WebDoctor Encyclopedia

Head & neck

Olfactory neuroblastoma (esthesioneuroblastoma)

Olfactory neuroblastoma (esthesioneuroblastoma) is a rare cancer that starts in the smell nerve lining at the top of the nose. It often causes a blocked nose and nosebleeds and is treated with surgery and radiotherapy.

Medically reviewed Last reviewed October 27, 2026

What is olfactory neuroblastoma?

Olfactory neuroblastoma is a rare cancer that starts high up inside the nose. It grows from the olfactory epithelium, the special lining at the roof of the nasal cavity that contains the nerve cells responsible for the sense of smell.

It is also widely known as esthesioneuroblastoma. The two names mean the same disease.

Despite the similar name, it is not the same as neuroblastoma, the childhood cancer of the adrenal glands and nerves. Olfactory neuroblastoma mostly affects adults, although it can occur at almost any age.

It makes up about 3-6% of cancers of the nose and sinuses. Its position just under the cribriform plate, the thin, sieve-like bone that separates the nose from the brain, is important because the tumour can grow upwards into the skull base and brain or sideways into the eye socket.

Early symptoms, such as a blocked nose and nosebleeds on one side, are easily mistaken for sinusitis or nasal polyps. Diagnosis is therefore often delayed.

With modern surgery and radiotherapy, many people are cured. The cancer can come back many years later, however, so long-term follow-up is essential.

1. Key facts at a glance

Feature Details
Type of cancer Neuroectodermal cancer of the olfactory (smell) lining
How common About 3-6% of nasal and sinus cancers; roughly 0.4 cases per million people a year
Typical age Any age; most often 40-70
Sex Men and women about equally
Main site Roof of the nasal cavity, near the cribriform plate
Spread Locally into sinuses, eye socket and brain; neck lymph nodes; rarely distant
Main treatments Surgery followed by radiotherapy; chemotherapy for advanced disease
Outlook About 70-80% alive at 5 years; late recurrences are common

2. Causes and risk factors

The cause of olfactory neuroblastoma is not known. Unlike some other nasal cancers, it has no clear link with wood dust, smoking or occupational chemicals.

Factor What is known
Age Can occur at any age, with most cases in middle age
Sex No strong difference
Smoking, wood dust, chemicals No proven link
Inherited conditions No known inherited syndrome
Previous radiation Rare reports after radiotherapy to the head

It is not infectious and is not passed on in families.

3. How does it look

Inside the nose

On examination with a thin camera (endoscope), the tumour usually appears as a soft, fleshy, reddish-grey or pink mass high in one side of the nose. It may look like a nasal polyp.

The tumour is often rich in blood vessels, so it may bleed easily when touched. Larger tumours can fill the nasal cavity and push the septum to the other side.

Visible changes on the face

Most early tumours cause no visible change. Larger tumours may cause:

Sign Description
Bulging eye One eye pushed forward (proptosis) from tumour in the eye socket
Swelling Fullness between the eyes or over the cheek
Watery eye Constant tearing from blockage of the tear duct
Neck lump A firm, painless swelling from lymph node spread

On scans

Scan What doctors may see
CT A soft-tissue mass at the roof of the nose with thinning or destruction of the cribriform plate and nearby bones
MRI Shows growth through the skull base; a “dumbbell” shape above and below the cribriform plate and small cysts at the brain edge are typical
PET-CT or DOTATATE PET Looks for spread to lymph nodes and distant sites; many tumours take up somatostatin-receptor tracers

Under the microscope

The pathologist sees lobules of small round blue cells separated by fibrous tissue. The cells often sit in a fine, fibrillary background made of nerve fibres.

Rosettes may be present. These are rings of tumour cells around a central core and are called Homer Wright or Flexner-Wintersteiner rosettes.

Marker Typical result
Synaptophysin, chromogranin Positive (nerve-endocrine features)
S100 Positive in supporting cells around the edges of the lobules
Cytokeratin Usually negative or only focal, which helps separate it from carcinomas
Ki-67 Shows how fast cells are dividing

Hyams grade

The tumour is graded using the Hyams system. Grades I and II are low grade, and grades III and IV are high grade.

Hyams grade Features Behaviour
I Well-formed lobules, plenty of fibrillary matrix, little cell division Slowest growing
II Similar, with slightly more atypia Low grade
III Less matrix, more cell division, some dead tissue High grade
IV Little or no matrix, marked atypia, much dead tissue Most aggressive

High-grade tumours carry a higher risk of spread and death (Goshtasbi et al., 2019).

4. Symptoms

Symptoms usually develop slowly over months or even years. Because they are so similar to common nasal problems, many people are first treated for sinusitis or allergies.

Common symptoms

  • Blocked nose on one side that does not clear; the most common symptom
  • Nosebleeds, often from one side and recurring
  • Reduced or lost sense of smell (hyposmia or anosmia)
  • Runny nose or discharge, sometimes blood-stained
  • Headache or pressure over the forehead or between the eyes
  • Recurrent sinus infections

Symptoms of more advanced disease

  • Bulging eye, double vision or reduced vision
  • Watery eye
  • A lump in the neck from lymph node spread
  • Personality change, seizures or confusion if the tumour grows into the front of the brain
  • Clear fluid dripping from the nose if the barrier between the nose and brain is breached

Rarely, the tumour produces hormones. It may cause low sodium levels (SIADH), leading to confusion, tiredness and nausea, or Cushing syndrome from ACTH production.

When to see a doctor

See your doctor if you have a blocked nose, nosebleeds or loss of smell on one side that lasts more than 3 weeks. One-sided symptoms that do not respond to usual treatment should be checked with an endoscopic examination by an ear, nose and throat (ENT) specialist.

Olfactory neuroblastoma in children and teenagers

Olfactory neuroblastoma is uncommon in children, but it does occur, mostly in teenagers. Young people often present with larger tumours, partly because nasal symptoms in this age group are usually blamed on colds or allergies.

Children are treated in specialist paediatric centres. Treatment combines surgery, radiotherapy and often chemotherapy, with particular care to limit the effects of radiotherapy on growth, hormones and learning.

5. Diagnosis

Test Purpose
Nasal endoscopy Looks directly at the mass inside the nose
CT of the sinuses Shows bone thinning or erosion
MRI of the head Shows spread into the eye socket, skull base and brain
Biopsy Confirms the diagnosis; usually taken under general anaesthetic after imaging
Neck ultrasound or MRI Checks for lymph node spread
PET-CT or DOTATATE PET Looks for distant spread in advanced or high-grade disease
Blood sodium and hormone tests If hormone symptoms are suspected

Under the microscope, olfactory neuroblastoma must be distinguished from other small round cell tumours of the nose. These include sinonasal undifferentiated carcinoma, neuroendocrine carcinoma, lymphoma, melanoma, rhabdomyosarcoma and Ewing sarcoma.

6. Staging

The most widely used system is the Kadish system (Kadish et al., 1976), later modified by Morita (Morita et al., 1993).

Kadish stage Extent of disease
A Limited to the nasal cavity
B Nasal cavity and one or more paranasal sinuses
C Beyond the nose and sinuses: eye socket, skull base, brain or cribriform plate
D (modified) Spread to neck lymph nodes or distant sites

Most people are diagnosed at stage B or C. A TNM-based system (Dulguerov) is also used in some centres.

7. Treatment

Treatment is planned by a skull base multidisciplinary team, including ENT surgeons, neurosurgeons, radiation oncologists and medical oncologists. Recent French consensus guidelines summarise current practice (Gorzkowski et al., 2026).

Surgery

Surgery to remove the tumour completely with clear margins is the most important treatment.

Approach Description
Endoscopic endonasal resection Performed through the nostrils with cameras; now the preferred approach in many centres for suitable tumours
Open craniofacial resection Combines an approach through the skull with one through the face or nose; used for very large tumours

To achieve clear margins, the surgeon usually removes the cribriform plate, the lining of the brain above it and the olfactory bulb. The skull base is then rebuilt, often using a flap of tissue from the inside of the nose.

Radiotherapy

Radiotherapy after surgery is given to most patients, especially those with stage B or higher, high-grade tumours or close margins. It reduces the risk of local recurrence.

Intensity-modulated radiotherapy (IMRT) or proton beam therapy is used to protect the eyes, optic nerves and brain. Radiotherapy to the neck may be added for advanced tumours, as neck spread is common later.

Chemotherapy

Situation Role of chemotherapy
Very large tumours Chemotherapy before surgery (induction) to shrink the tumour, often cisplatin and etoposide
High-grade tumours May be combined with radiotherapy
Spread to distant sites Main treatment, with radiotherapy for symptoms
Recurrence Chemotherapy, further surgery or radiotherapy; somatostatin-targeted treatments are being explored

Neck lymph nodes

Lymph node spread is present in a small proportion of people at diagnosis, but it can develop years later (Kuan et al., 2019). If nodes are involved, a neck dissection and radiotherapy are performed.

8. Outlook (prognosis)

The outlook for olfactory neuroblastoma is generally good compared with many other skull base cancers. Large studies report 5-year survival of roughly 70-80%, and higher in some modern series (Abdelmeguid et al., 2022).

Factor Effect on outlook
Kadish stage Stages A and B do best; stage D has the poorest outlook
Hyams grade Low-grade tumours do much better than high-grade
Clear surgical margins Strongly linked with better control
Postoperative radiotherapy Lowers the risk of local recurrence
Neck node spread Poorer outlook

A meta-analysis found that grade and lymph node spread were among the strongest predictors of survival (Dulguerov et al., 2001).

Late recurrence

A distinctive feature of olfactory neuroblastoma is its tendency to return many years later, sometimes after 10 years or more. Recurrences may occur at the original site, in the neck or, less often, elsewhere.

For this reason, follow-up usually continues for life or at least 10-15 years.

9. Living with olfactory neuroblastoma

Concern What helps
Loss of smell Usually permanent after surgery; fit smoke and gas alarms, check food dates, and label leftovers
Taste changes Flavour depends on smell; experimenting with texture, spices and temperature can help
Nasal crusting Regular saline rinses, especially after surgery and radiotherapy
Dry eyes and vision Eye checks during and after radiotherapy
Hormone changes Radiotherapy near the pituitary gland may affect hormones; yearly blood tests are often advised
Emotional effects Support from specialist nurses, psychologists and head and neck cancer groups

Follow-up

Follow-up includes nasal endoscopy and MRI of the head and neck. These are usually done every 3-4 months in the first two years, then less often, and continue long term.

10. Frequently asked questions

Question Answer
Is it the same as childhood neuroblastoma? No. Despite the similar name, it is a different cancer
Will I lose my sense of smell? Usually yes, as the smell nerves are removed or affected by treatment
Do I need brain surgery? The surgery involves the skull base, but it can often be done through the nose without opening the skull
Can it be cured? Yes, many people are cured, especially with early-stage, low-grade tumours
Why is follow-up so long? Because this cancer can come back many years after treatment

11. Questions to ask your care team

  • What Kadish stage and Hyams grade is my tumour?
  • Can it be removed endoscopically through the nose?
  • Will I need radiotherapy, and is proton therapy an option?
  • Is chemotherapy recommended before or after surgery?
  • Will my neck be treated?
  • How long will my follow-up last?

Resources

  1. Kadish, S., Goodman, M. and Wang, C.C. (1976) ‘Olfactory neuroblastoma. A clinical analysis of 17 cases’, Cancer, 37(3), pp. 1571-1576.
  2. Morita, A. et al. (1993) ‘Esthesioneuroblastoma: prognosis and management’, Neurosurgery, 32(5), pp. 706-714.
  3. Dulguerov, P., Allal, A.S. and Calcaterra, T.C. (2001) ‘Esthesioneuroblastoma: a meta-analysis and review’, The Lancet Oncology, 2(11), pp. 683-690.
  4. Goshtasbi, K. et al. (2019) ‘Hyams grading as a predictor of metastasis and overall survival in esthesioneuroblastoma: a meta-analysis’, International Forum of Allergy and Rhinology, 9(9), pp. 1054-1062.
  5. Kuan, E.C. et al. (2019) ‘A population-based analysis of nodal metastases in esthesioneuroblastomas of the sinonasal tract’, The Laryngoscope, 129(5), pp. 1025-1029.
  6. Abdelmeguid, A.S. et al. (2022) ‘Long-term outcomes of olfactory neuroblastoma: MD Anderson Cancer Center experience and review of the literature’, The Laryngoscope, 132(2), pp. 290-297.
  7. Fiani, B. et al. (2019) ‘Esthesioneuroblastoma: a comprehensive review of diagnosis, management, and current treatment options’, World Neurosurgery, 126, pp. 194-211.
  8. Gorzkowski, V. et al. (2026) ‘REFCOR guidelines on the management of olfactory neuroblastoma: a formalized expert consensus’, European Annals of Otorhinolaryngology, Head and Neck Diseases, 143(4), pp. 325-329.
  9. National Cancer Institute (2026) Paranasal Sinus and Nasal Cavity Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/head-and-neck/hp/adult/paranasal-sinus-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.